AU2002340669A1 - Lipid carrier compositions with enhanced blood stability - Google Patents

Lipid carrier compositions with enhanced blood stability

Info

Publication number
AU2002340669A1
AU2002340669A1 AU2002340669A AU2002340669A AU2002340669A1 AU 2002340669 A1 AU2002340669 A1 AU 2002340669A1 AU 2002340669 A AU2002340669 A AU 2002340669A AU 2002340669 A AU2002340669 A AU 2002340669A AU 2002340669 A1 AU2002340669 A1 AU 2002340669A1
Authority
AU
Australia
Prior art keywords
lipid carrier
carrier compositions
enhanced blood
blood stability
stability
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002340669A
Inventor
Ludger M. Ickenstein
Lawrence D. Mayer
Paul Tardi
Murray Webb
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CELATOR TECHNOLOGIES Inc
Original Assignee
CELATOR TECHNOLOGIES Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CELATOR TECHNOLOGIES Inc filed Critical CELATOR TECHNOLOGIES Inc
Publication of AU2002340669A1 publication Critical patent/AU2002340669A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
AU2002340669A 2001-11-13 2002-11-13 Lipid carrier compositions with enhanced blood stability Abandoned AU2002340669A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US33124801P 2001-11-13 2001-11-13
US60/331,248 2001-11-13
US39427102P 2002-07-09 2002-07-09
US60/394,271 2002-07-09
PCT/CA2002/001726 WO2003041681A2 (en) 2001-11-13 2002-11-13 Lipid carrier compositions with enhanced blood stability

Publications (1)

Publication Number Publication Date
AU2002340669A1 true AU2002340669A1 (en) 2003-05-26

Family

ID=26987658

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002340669A Abandoned AU2002340669A1 (en) 2001-11-13 2002-11-13 Lipid carrier compositions with enhanced blood stability

Country Status (8)

Country Link
US (3) US20050118250A1 (en)
EP (1) EP1443900B1 (en)
JP (2) JP4555569B2 (en)
AU (1) AU2002340669A1 (en)
CA (1) CA2467064C (en)
ES (1) ES2387886T3 (en)
PT (1) PT1443900E (en)
WO (1) WO2003041681A2 (en)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2387886T3 (en) * 2001-11-13 2012-10-03 Celator Pharmaceuticals, Inc. Compositions that transport lipids with better blood stability
AU2003295954A1 (en) * 2002-11-26 2004-06-18 Gilead Sciences, Inc. Method of drug loading in liposomes by gradient
US8980310B2 (en) * 2002-12-31 2015-03-17 Bharat Serums and Vaccines, Ltd. Non-pegylated long-circulating liposomes
WO2005002546A1 (en) * 2003-06-27 2005-01-13 Smithkline Beecham Corporation Stabilized topotecan liposomal composition and methods
CN107811971B (en) 2004-05-03 2021-10-29 益普生生物制药公司 Liposomes for drug delivery
JP4885715B2 (en) * 2004-06-01 2012-02-29 テルモ株式会社 Irinotecan formulation
JP4715133B2 (en) * 2004-08-26 2011-07-06 コニカミノルタエムジー株式会社 Anti-tumor liposome preparation and production method thereof
WO2006052767A2 (en) * 2004-11-05 2006-05-18 Inex Pharmaceuticals Corporation Compositions and methods for stabilizing liposomal camptothecin formulations
US20110020434A1 (en) * 2005-09-02 2011-01-27 O'halloran Thomas V Nanoparticle arsenic-platinum compositions
US20070154403A1 (en) * 2006-01-05 2007-07-05 Thomas Skold Oral, Pulmonary and Transmucosal Delivery Composition
WO2007117469A2 (en) * 2006-03-30 2007-10-18 The Research Foundation Of State University Of New York Compositions of less immunogenic and long-circulating protein-lipid complexes
EP2356990A3 (en) * 2006-08-02 2011-10-19 University of Oxford Liposome treatment of viral infections
US20090196917A1 (en) * 2008-02-01 2009-08-06 University Of Kentucky Research Foundation Liposomal Formulations of Hydrophobic Lactone Drugs in the Presence of Metal Ions
KR20100127842A (en) * 2008-03-26 2010-12-06 유니버시티 오브 옥스퍼드 Endoplasmic reticulum targeting liposomes
EP2123258A1 (en) 2008-05-23 2009-11-25 Liplasome Pharma A/S Liposomes for drug delivery
AR076634A1 (en) * 2008-11-21 2011-06-29 Medgenesis Therapeutix Inc COMPOSITIONS AND METHOD TO TREAT CENTRAL NERVOUS SYSTEM DISORDERS
WO2010109330A2 (en) * 2009-03-27 2010-09-30 University Of Oxford Cholesterol level lowering liposomes
EP2415464B1 (en) 2009-03-30 2017-05-10 Eisai R&D Management Co., Ltd. Method for producing liposome composition
US20120058178A1 (en) 2009-03-30 2012-03-08 Eisai R&D Management Co., Ltd. Liposome Composition
DK177532B1 (en) * 2009-09-17 2013-09-08 Bio Bedst Aps Medical use of sPLA2 hydrolysable liposomes
DK177529B1 (en) 2009-10-23 2013-09-08 Bio Bedst Aps Liposomes with improved storage stability
PL2508170T3 (en) * 2009-12-03 2015-12-31 Jiangsu Hengrui Medicine Co Liposome of irinotecan or its hydrochloride and preparation method thereof
CN107261110A (en) * 2010-06-19 2017-10-20 健康科学西部大学 The novel formulation of the liposomal encapsulated glycopeptide antibiotic of PEGylation
ITMI20111271A1 (en) * 2011-07-08 2013-01-09 Giuseppe Milani FOOD PRODUCT OF THE TYPE TO BE STORED AND CONSUMED REFRIGERATED OR FROZEN
KR102113753B1 (en) * 2011-10-21 2020-05-21 셀라토 파마슈티칼즈, 인코포레이티드 Lyophilized liposomes
EP3782606A1 (en) * 2012-06-14 2021-02-24 Universität Bern Tailored liposomes for the treatment of bacterial infections
KR102310697B1 (en) 2012-11-20 2021-10-12 스펙트럼 파마슈티컬즈 인크 Improved method for the preparation of liposome encapsulated vincristine for therapeutic use
WO2014153114A1 (en) * 2013-03-14 2014-09-25 Fred Hutchinson Cancer Research Center Compositions and methods to modify cells for therapeutic objectives
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
EP3138555B1 (en) * 2014-04-30 2020-10-28 FUJIFILM Corporation Liposome composition and production method therefor
TWI678213B (en) 2015-07-22 2019-12-01 美商史倍壯製藥公司 A ready-to-use formulation for vincristine sulfate liposome injection
BR112018006922B1 (en) 2015-10-16 2023-11-21 Ipsen Biopharm Ltd LIPOSOMAL IRINOTECAN COMPOSITIONS STABILIZED FOR STORAGE
US10188749B2 (en) 2016-04-14 2019-01-29 Fred Hutchinson Cancer Research Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (en) 2016-07-22 2017-11-30 Flamel Ireland Ltd FORMULATIONS OF GAMMA-MODIFIED RELEASE HYDROXIBUTIRATE WITH IMPROVED PHARMACOCINETICS
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
AU2017258901A1 (en) 2016-12-30 2018-07-19 Allarity Therapeutics Europe ApS Methods for predicting drug responsiveness in cancer patients
CA3062426A1 (en) 2017-05-08 2018-11-15 Flagship Pioneering Innovations V, Inc. Compositions for facilitating membrane fusion and uses thereof
US10459751B2 (en) * 2017-06-30 2019-10-29 ATI Technologies ULC. Varying firmware for virtualized device
AU2019210204A1 (en) * 2018-01-18 2020-08-13 EndoProtech, Inc. Treating microvascular dysfunction
AU2019339401B9 (en) * 2018-09-14 2022-11-03 Pharmosa Biopharm Inc. Pharmaceutical composition for controlled release of weak acid drugs and uses thereof
MX2021006912A (en) 2018-12-11 2021-08-24 Disruption Labs Inc Compositions for the delivery of therapeutic agents and methods of use and making thereof.
CA3127871A1 (en) 2019-03-01 2020-09-10 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US11083705B2 (en) 2019-07-26 2021-08-10 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
EP4188552A2 (en) 2020-07-28 2023-06-07 Jazz Pharmaceuticals Ireland Limited Fused bicyclic raf inhibitors and methods for use thereof
AU2021318923A1 (en) 2020-07-28 2023-03-09 Jazz Pharmaceuticals Ireland Limited Chiral synthesis of fused bicyclic Raf inhibitors
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5077056A (en) 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
ATE78158T1 (en) * 1985-05-22 1992-08-15 Liposome Technology Inc METHOD AND SYSTEM FOR INHALATION OF LIPOSOMES.
IE58981B1 (en) 1985-10-15 1993-12-15 Vestar Inc Anthracycline antineoplastic agents encapsulated in phospholipid micellular particles
JPH0617309B2 (en) 1985-11-29 1994-03-09 株式会社ビタミン研究所 Adriamycin embedded liposome preparation
US4927571A (en) 1987-05-18 1990-05-22 Liposome Technology, Inc. Preparation of injectable doxorubicin/liposome suspension
AU598958B2 (en) * 1987-11-12 1990-07-05 Vestar, Inc. Improved amphotericin b liposome preparation
US4915951A (en) 1987-12-03 1990-04-10 California Institute Of Technology Cryoprotective reagent
JP2792702B2 (en) * 1988-10-05 1998-09-03 ネクスター・フアーマシユーテイカルズ・インコーポレイテツド Method for preparing liposomes with improved stability when dried
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5843473A (en) * 1989-10-20 1998-12-01 Sequus Pharmaceuticals, Inc. Method of treatment of infected tissues
IS1685B (en) * 1990-12-11 1998-02-24 Bracco International B.V. Method of making liposomes that are endowed with enhanced ability to absorb and contain foreign matter
GB9111611D0 (en) * 1991-05-30 1991-07-24 Sandoz Ltd Liposomes
US5648532A (en) * 1993-06-03 1997-07-15 The Regents Of The University Of California Compositions for boron neutron capture therapy and methods thereof
US5415869A (en) 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
PT101422B (en) 1993-12-06 1997-06-30 Ineti Inst Biotec Q F E Tecnol LIPOSOMAL FORMULATIONS CONTAINING VIDARABINE AND / OR DERIVATIVES, WITH A HIGH THERAPEUTIC INDEX AND PROCESS FOR THEIR PREPARATION
US6139871A (en) 1995-07-26 2000-10-31 The University Of British Columbia Liposome compositions and methods for the treatment of atherosclerosis
JPH07316041A (en) 1994-03-28 1995-12-05 Dai Ichi Seiyaku Co Ltd Liposome with improved entrapping capacity
WO1995026185A1 (en) 1994-03-28 1995-10-05 Daiichi Pharmaceutical Co., Ltd. Liposome with increased retention volume
CA2201631C (en) * 1994-10-03 2004-05-04 Michel G. Bergeron Liposome-formulations for treatment of viral diseases
PT929293E (en) * 1996-08-23 2004-03-31 Sequus Pharm Inc LIPOSOMES CONTAINING A COMPOSITE OF CISPLATIN
US6120800A (en) * 1997-09-25 2000-09-19 Nexstar Pharmaceuticals, Inc. Vinca-alkaloid vesicles with enhanced efficacy and tumor targeting properties
WO1999027908A1 (en) 1997-12-04 1999-06-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Combined chemo-immunotherapy with liposomal drugs and cytokines
JPH11171772A (en) 1997-12-11 1999-06-29 Sankyo Co Ltd Liposome preparation of antitumor medicine
WO1999059547A1 (en) 1998-05-21 1999-11-25 Isis Pharmaceuticals, Inc. Long-circulating liposomal compositions
US6200598B1 (en) * 1998-06-18 2001-03-13 Duke University Temperature-sensitive liposomal formulation
US6270806B1 (en) 1999-03-03 2001-08-07 Elan Pharma International Limited Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions
JP2001026544A (en) 1999-05-11 2001-01-30 Sankyo Co Ltd Liposome formulation of oil-soluble antitumor agent
AU775038B2 (en) 1999-07-16 2004-07-15 Alza Corporation A liposome composition having resistance to freeze/thaw damage
JP2001302496A (en) 2000-04-14 2001-10-31 Takeda Chem Ind Ltd Liposome preparation
JP4540287B2 (en) 2001-03-02 2010-09-08 日油株式会社 Process for producing polyalkylene oxide-modified phospholipids
DE60208454T2 (en) 2001-03-02 2006-09-07 Nof Corp. Polyalkylene oxide-modified phospholipids and process for their preparation
ES2387886T3 (en) * 2001-11-13 2012-10-03 Celator Pharmaceuticals, Inc. Compositions that transport lipids with better blood stability

Also Published As

Publication number Publication date
JP2010018632A (en) 2010-01-28
JP4555569B2 (en) 2010-10-06
EP1443900A2 (en) 2004-08-11
WO2003041681A2 (en) 2003-05-22
US20030124181A1 (en) 2003-07-03
JP2005509000A (en) 2005-04-07
CA2467064C (en) 2011-02-08
ES2387886T3 (en) 2012-10-03
EP1443900B1 (en) 2012-05-23
CA2467064A1 (en) 2003-05-22
US8518437B2 (en) 2013-08-27
US20050118250A1 (en) 2005-06-02
WO2003041681A3 (en) 2003-09-18
US20110002982A1 (en) 2011-01-06
PT1443900E (en) 2012-08-01

Similar Documents

Publication Publication Date Title
AU2002340669A1 (en) Lipid carrier compositions with enhanced blood stability
AU2002364573A1 (en) Dynamic cannula
AU2002330273A1 (en) Liposome-encapsulated insulin formulations
AU2002313236A1 (en) Medicinal compositions
AU2002317568A1 (en) Technical field
AU2002253039A1 (en) Tramadol-based medicament
AU2002359919A1 (en) Syringe
AU2002361092A1 (en) Syringe
AU2002343312A1 (en) Two fixed-beams tx-diversity
AU2002221131A1 (en) Blood lipid ameliorant composition
AU2002211005A1 (en) Lipid peroxide-lowering compositions
AU2002365860A1 (en) Clothes-hanger
AU2002349142A1 (en) Syringe
AU2002221130A1 (en) Blood lipid ameliorant composition
AU2002257904A1 (en) Polythiourea lipid derivatives
AU2002351944A1 (en) Aortic cannula
AU2002238946A1 (en) Pharmacuetical composition
AU2002318808A1 (en) Photodetector
AU2002228562A1 (en) Supplemental preparation
AU2002325912A1 (en) Shelving component
AU2002317314A1 (en) Leukocyte preparation
AU785403B2 (en) Chair
AU2002313723A1 (en) Anticoagulant compounds
AU2002239247A1 (en) Split sock
AU2002343546A1 (en) Beta-carbolin derivatives as ptp-inhibitors

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase